This clinical stage start-up biotech company focuses on using microbiome-derived metabolites as drugs to treat cancer, liver, and auto-immune diseases. Their proprietary platform is based on immuno-modulation of inflammatory factors discovered in the human gut microbiome, and is licensed from research at Temple University in Philadelphia. SFA Therapeutics' products are a unique native immunotherapy platform with promising activity currently being investigated in clinical trials.